Loading…
Loading…
Envista NVST is scheduled to release third-quarter 2026 results on Nov. 4, after the closing bell.
Envista (NVST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BREA, Calif., Oct. 27, 2026 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") today announced the publication of its 2025 Sustainability Report.
Envista (NYSE: NVST - Get Free Report) and MariMed (OTCMKTS:MRMD - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability and analyst recommendations. Analyst Recommendations This is a summary of recent ratings and
Envista Holdings Corporation (NYSE: NVST - Get Free Report) has received a consensus rating of "Hold" from the seventeen ratings firms that are currently covering the stock, Marketbeat Ratings reports. Ten research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12 month price
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Keel purchased 4,701 shares at $53.18 each following a 21% year-long decline, signaling confidence in the medical device company's valuation.